FCM
BSX icon

Farallon Capital Management’s Boston Scientific BSX Stock Holding History

Farallon Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$469M Buy
7,470,684
+31,120
+0.4% +$2.49M 2.67% 14
2025
Q4 		$709M Buy
7,439,564
+2,693,007
+57% +$264M 3.21% 7
2025
Q3 		$463M Buy
4,746,557
+765,500
+19% +$79.3M 1.9% 16
2025
Q2 		$428M Buy
3,981,057
+218,300
+6% +$22.1M 1.8% 20
2025
Q1 		$380M Sell
3,762,757
-1,260,200
-25% -$127M 1.82% 21
2024
Q4 		$449M Sell
5,022,957
-402,700
-7% -$35.4M 1.97% 19
2024
Q3 		$455M Buy
5,425,657
+1,316,500
+32% +$104M 1.99% 16
2024
Q2 		$316M Sell
4,109,157
-487,500
-11% -$35.7M 1.36% 27
2024
Q1 		$315M Sell
4,596,657
-1,223,600
-21% -$78.7M 1.34% 22
2023
Q4 		$336M Buy
5,820,257
+781,000
+15% +$41.7M 1.54% 18
2023
Q3 		$266M Sell
5,039,257
-6,000
-0.1% -$315K 1.24% 27
2023
Q2 		$273M Sell
5,045,257
-2,660,000
-35% -$139M 1.37% 28
2023
Q1 		$385M Sell
7,705,257
-1,555,000
-17% -$73.3M 2.11% 16
2022
Q4 		$428M Sell
9,260,257
-2,891,000
-24% -$125M 2.53% 7
2022
Q3 		$471M Sell
12,151,257
-2,896,000
-19% -$116M 2.58% 6
2022
Q2 		$561M Sell
15,047,257
-693,000
-4% -$28.2M 3.04% 5
2022
Q1 		$697M Sell
15,740,257
-1,074,324
-6% -$46.6M 3.36% 4
2021
Q4 		$714M Buy
16,814,581
+2,812,000
+20% +$118M 3.57% 4
2021
Q3 		$608M Buy
14,002,581
+1,285,962
+10% +$56.9M 2.84% 4
2021
Q2 		$544M Sell
12,716,619
-106,250
-0.8% -$4.47M 2.22% 9
2021
Q1 		$496M Sell
12,822,869
-415,450
-3% -$15.7M 2.46% 9
2020
Q4 		$476M Buy
13,238,319
+4,962,400
+60% +$179M 2.86% 8
2020
Q3 		$316M Buy
+8,275,919
New +$319M 2.19% 17

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Farallon Capital Management's BSX Position: Q1 2026 in Review

Farallon Capital Management increased its Boston Scientific (BSX) stake by 0.42% in Q1 2026, buying an estimated $2.49M and bringing the position to 7,470,684 shares worth $469M. The position accounts for 2.67% of the portfolio, ranked #14.

Farallon Capital Management first reported a position in BSX in Q3 2020 and has held it in 23 quarters since. The position peaked at $714M in Q4 2021. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Farallon Capital Management held 7,470,684 shares of Boston Scientific worth $469M as of Q1 2026.
  • Farallon Capital Management bought 31,120 Boston Scientific shares in Q1 2026, an estimated $2.49M.
  • Boston Scientific made up 2.67% of Farallon Capital Management's portfolio in Q1 2026, its #14 holding.
  • Farallon Capital Management first reported a position in Boston Scientific in Q3 2020 and has held it in 23 quarters since.
  • Farallon Capital Management's Boston Scientific position peaked at $714M in Q4 2021.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.